Search results
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks via Yahoo Finance· 12 hours agoBristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it...
Bristol-Myers Squibb (NYSE:BMY) Shares Down 1.1%
ETF DAILY NEWS· 6 days agoShares of Bristol-Myers Squibb (NYSE:BMY – Get Free Report) fell 1.1% during trading on Thursday . The company traded as low as $41.58 and last traded at $41.89. 3,501,801 shares changed hands ...
Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking - Bristol-Myers Squibb...
Benzinga· 8 hours agoVolume & Open Interest Development Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you track the liquidity ...
Q2 2025 Earnings Estimate for Bristol-Myers Squibb Issued By Zacks Research (NYSE:BMY)
ETF DAILY NEWS· 3 days agoBristol-Myers Squibb (NYSE:BMY – Free Report) – Investment analysts at Zacks Research raised their Q2 2025 earnings estimates for shares of Bristol-Myers Squibb in a research report issued on ...
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
Zacks· 20 hours agoFree Report) announced that the European Commission (EC) has approved its blockbuster immuno-oncology drug, Opdivo (nivolumab), in combination with a chemotherapy combination, cisplatin and ...
Bristol Myers Squibb Shares Cross 6% Yield Mark
Forbes· 2 days agoIn trading on Wednesday, shares of Bristol Myers Squibb were yielding above the 6% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands ...
Bristol-Myers Squibb Co. [BMY] Investment Appeal on the Rise – Knox Daily
Knox Daily· 2 days ago[BMY] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Redburn Atlantic’s analysts, who decreased its forecast ...
7 Underappreciated Stocks With 25% Return Potential in 2024
InvestorPlace· 15 hours agoWhether investors refer to them as undervalued or hidden gems, underappreciated stocks are always...
Is It Too Late to Buy Vertex Pharmaceuticals Stock? | The Motley Fool
The Motley Fool· 4 days agoVertex Pharmaceuticals (VRTX 1.36%) is a fast-growing pharmaceutical company that investors have...
This Pharma Stock Is Poised to Keep Outperforming the S&P 500 | The Motley Fool
The Motley Fool· 14 hours agoAstraZeneca (AZN 0.91%), recognized as the world's sixth-largest pharmaceutical entity by market...